Peter F. Surai,Anton Surai,Katie Earle-Payne
Abstract:Inflammation is a vital defense mechanism, creating hostile conditions for pathogens, preventing the spread of tissue infection and repairing damaged tissues in humans and animals. However, when inflammation resolution is delayed or compromised as a result of its misregulation, the process proceeds from the acute phase to chronic inflammation, leading to the development of various chronic illnesses. It is proven that redox balance disturbances and oxidative stress are among major factors inducing NF-κB and leading to over-inflammation. Therefore, the anti-inflammatory properties of various natural antioxidants have been widely tested in various in vitro and in vivo systems. Accumulating evidence indicates that silymarin (SM) and its main constituent silibinin/silybin (SB) have great potential as an anti-inflammation agent. The main anti-inflammatory mechanism of SM/SB action is attributed to the inhibition of TLR4/NF-κB-mediated signaling pathways and the downregulated expression of pro-inflammatory mediators, including TNF-α, IL-1β, IL-6, IL-12, IL-23, CCL4, CXCL10, etc. Of note, in the same model systems, SM/SB was able to upregulate anti-inflammatory cytokines (IL-4, IL-10, IL-13, TGF-β, etc.) and lipid mediators involved in the resolution of inflammation. The inflammatory properties of SM/SB were clearly demonstrated in model systems based on immune (macrophages and monocytes) and non-immune (epithelial, skin, bone, connective tissue and cancer) cells. At the same time, the anti-inflammatory action of SM/SB was confirmed in a number of in vivo models, including toxicity models, nonalcoholic fatty liver disease, ischemia/reperfusion models, stress-induced injuries, ageing and exercising models, wound healing and many other relevant model systems. It seems likely that the anti-inflammatory activities of SM/SB are key elements on the health-promoting properties of these phytochemicals.
What problem does this paper attempt to address?
The paper attempts to address the potential anti-inflammatory effects of Silymarin and its main component Silibinin/Silybin. Specifically, the paper focuses on the following aspects:
1. **Background of Inflammation**:
- Inflammation is an important defense mechanism in humans and animals that can combat pathogens, prevent the spread of tissue infections, and repair damaged tissues.
- When the resolution process of inflammation is delayed or impaired due to immune response dysregulation, acute inflammation can evolve into chronic inflammation, leading to various chronic diseases such as atherosclerosis, cancer, obesity, asthma, chronic obstructive pulmonary disease, multiple sclerosis, inflammatory bowel disease, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis), and autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and celiac disease).
2. **Relationship between Oxidative Stress and Inflammation**:
- Disruption of redox balance and oxidative stress are major factors inducing NF-κB activation and excessive inflammation.
- Dysregulation of the antioxidant network can lead to oxidative stress, thereby triggering inflammation.
3. **Anti-inflammatory Mechanisms of Silymarin**:
- Silymarin and its main component Silibinin exert their anti-inflammatory effects by inhibiting the TLR4/NF-κB-mediated signaling pathway and downregulating the expression of pro-inflammatory mediators (such as TNF-α, IL-1β, IL-6, IL-12, IL-23, CCL4, CXCL10, etc.).
- At the same time, Silymarin can upregulate the expression of anti-inflammatory cytokines (such as IL-4, IL-10, IL-13, TGF-β, etc.) and lipid mediators involved in the resolution of inflammation.
4. **Experimental Validation**:
- The paper reviews a large number of in vitro and in vivo experimental results, demonstrating the anti-inflammatory effects of Silymarin and its main component in various model systems, including immune cells (macrophages and monocytes) and non-immune cells (epithelial cells, skin cells, bone cells, connective tissue cells, and cancer cells).
- In in vivo models, the anti-inflammatory effects of Silymarin have also been validated in various models, including toxicity models, non-alcoholic fatty liver disease, ischemia/reperfusion models, stress-induced injury, aging and exercise models, wound healing, etc.
In summary, this paper aims to comprehensively summarize and update the research progress on the anti-inflammatory effects of Silymarin and its main component Silibinin, with particular emphasis on their molecular mechanisms and protective effects.